Home Team Round tour Contact Your view Sitemap Imprint
German English Persian Greek

Practice for ENT and facial plastic surgery

Mehran Baghi, MD, PhD (ENT and facial plastic surgeon)
Khairallah El-Cheikh MD (ENT surgeon, holidays representation)

Logo

Dr. med. Mehran Baghi

Dr. med. Mehran Baghi is a specialist for ENT, head and neck surgery, plastic and aesthetic surgery and attending physician at the Hospital Ketteler in Offenbach am Main. He has completed his final clinical practice as deputy and assistant medical director of the Johann Wolfgang Goethe University hospital in Frankfrut by June 2009.

His original interest in the plastic surgery has been the main reason to specialise in many different subjects of medicine. Due to his scientific background Dr Baghi is a welcomed guest lecturer on national and international meetings.

e-mail
info@hno-drbaghi.com

Qualifications
  • Plastic and aestetic surgery (rhinoplasty, otoplasty)
  • Paranasal Sinus surgery, functional endoscopic sinus surgery (FESS)
  • Reconstructive surgery in head and neck, including microvascular techniques
  • Parotid gland surgery
  • Sleep Apnea surgery
  • Laser surgery
Vita Dr. med. Mehran Baghi

Postgraduate Education

2009 private ENT- Practice and Clinic
2009 Plastic facial surgery
2005 - 2009 Attending physician at the university hospital, ENT department, Frankfurt am Main, Germany ,
Field: Head and Neck Oncology, reconstructive surgery ,
Head: Prof. Gstoettner
2008 Associate professor at the university ENT Clinic
2005 German Board of ENT (Facharzt)
1999- 2005 Resident at the university hospital, ENT department, Frankfurt am Main, Germany, Head: Prof. Gstoettner


Education

1992- 1999 Graduate training
Medical school, university of Tuebingen/ Germany
Medical school, university of Bern/ Switzerland
General Hospital of Reutlingen/ Germany
General Hospital of Stuttgart/ Germany
Graduation: May 5th, 1999
1988 - 1991 High School education, Duesseldorf, Germany, Graduation: June 1991


Qualifications

1995-1998 Research fellow at the university hospital, department for maxiallofacial surgery,
Head: Prof. Dr. Dr. N. Schwenzer
1995-1998 Anatomy tutor, anatomical department, university of Tuebingen, Germany,
Head: Prof. Drews
1995-2000 Doctoral dissertation at the university hospital, department for maxillofacial surgery, Tuebingen, Germany, Title: Significance of 99m- Tc- Bone Scan Scintigraphy in staging of patients with SCC in Head and Neck


Clinical Skills

  • All major surgical procedures in field of Otolaryngology
  • Neck surgery, endolaryngeal Co2- laser surgery, Rhinoplasty, FESS, plastic reconstructive procedures,
    parotid gland surgery, microvascular flaps, ear surgery
  • Special emphasis on Oncology & plastic, reconstructive surgery


Memberships of professional societies

  • German Medical Council, 1999
  • German Society of otolaryngology (DGHNO), 1999
  • German Academy of otolaryngology, 2001
  • European Academy of facial plastic surgery (EAFPS), 2003
  • American Academy of Otolaryngology , Head and Neck Surgery (AAO HNS), 2003
  • Iranian Medical Council, Reg.No: 110363, 2006
Publications
  1. Perfusion CT in Squamous Cell Carcinoma of the Upper Aerodigestive Tract: Long-Term Predictive Value of Baseline Perfusion CT Measurements
    Bisdas S, Rumboldt Z, Popovic KS, Baghi M, Koh TS, Vogl TJ, Mack MG.
    AJNR Am J Neuroradiol. 2009 Oct 29. [Epub ahead of print]
  2. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
    Wagenblast J, Baghi M, Mörtel S, Hirth D, Thron L, Arnoldner C, Gstöttner W, May A, Hambek M.
    Oncol Rep. 2009 Jul;22(1):171-6.
  3. Tracer kinetics analysis of dynamic contrast-enhanced CT and MR data in patients with squamous cell carcinoma of the upper aerodigestive tract: comparison of the results.
    Bisdas S, Baghi M, Wagenblast J, Bisdas T, Thng CH, Mack MG, Koh TS, Ernemann U.
    Clin Physiol Funct Imaging. 2009 Sep;29(5):339-46. Epub 2009 May 15.
  4. Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements.
    Bisdas S, Rumboldt Z, Wagenblast J, Baghi M, Koh TS, Hambek M, Vogl TJ, Mack MG.
    AJNR Am J Neuroradiol. 2009 Apr;30(4):793-9.
  5. Dynamic contrast-enhanced CT of head and neck tumors: comparison of first-pass and permeability perfusion measurements using two different commercially available tracer kinetics models.
    Bisdas S, Konstantinou G, Surlan-Popovic K, Khoshneviszadeh A, Baghi M, Vogl TJ, Koh TS, Mack MG.
    Acad Radiol. 2008 Dec;15(12):1580-9.
  6. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
    Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, May A, Knecht R, Hambek M.
    Oncol Rep. 2008 Nov;20(5):1207-11.
  7. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
    Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Hambek M, Knecht R.
    J Cancer Res Clin Oncol. 2009 Mar;135(3):387-93. Epub 2008 Oct 1.
  8. Craniofacial reconstructions with bone-anchored epithesis in head and neck cancer patients--a valid way back to self-perception and social reintegration.
    Wagenblast J, Baghi M, Helbig M, Arnoldner C, Bisdas S, Gstöttner W, Hambek M, May A.
    Anticancer Res. 2008 Jul-Aug;28(4C):2349-52.
  9. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
    Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Knecht R, Hambek M.
    Anticancer Res. 2008 Jul-Aug;28(4B):2239-43.
  10. Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma.
    Tselis N, Heyd R, Baghi M, Zamboglou N.
    Laryngoscope. 2008 Nov;118(11):2006-10.
  11. Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
    Baghi M, Wagenblast J, Hambek M, Moertel S, Gstöttner W, Strebhardt K, Knecht R.
    Clin Otolaryngol. 2008 Jun;33(3):245-51.
  12. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
    Wagenblast J, Hambek M, Baghi M, Knecht R.
    Anticancer Res. 2008 Mar-Apr;28(2A):687-92.
  13. Gadolinium-enhanced echo-planar T2-weighted MRI of tumors in the extracranial head and neck: feasibility study and preliminary results using a distributed-parameter tracer kinetic analysis.
    Bisdas S, Baghi M, Wagenblast J, Vogl TJ, Thng CH, Koh TS.
    J Magn Reson Imaging. 2008 May;27(5):963-9.
  14. Cervical lymph nodes.
    Mack MG, Rieger J, Baghi M, Bisdas S, Vogl TJ.
    Eur J Radiol. 2008 Jun;66(3):493-500. Epub 2008 Mar 11. Review.
  15. A comparison of tumour perfusion assessed by deconvolution-based analysis of dynamic contrast-enhanced CT and MR imaging in patients with squamous cell carcinoma of the upper aerodigestive tract.
    Bisdas S, Medov L, Baghi M, Konstantinou GN, Wagenblast J, Thng CH, Vogl TJ, Koh TS.
    Eur Radiol. 2008 Apr;18(4):843-50. Epub 2008 Jan 4.
  16. Variance of angular insertion depths in free-fitting and perimodiolar cochlear implant electrodes.
    Radeloff A, Mack M, Baghi M, Gstöttner WK, Adunka OF.
    Otol Neurotol. 2008 Feb;29(2):131-6.
  17. [Imaging in inflammatory diseases of the paranasal sinuses]
    Mack MG, May A, Bisdas S, Baghi M, Vogl TJ.
    Radiologe. 2007 Jul;47(7):606-12. Review. German.
  18. Iron oxide particle-enhanced magnetic resonance imaging for detection of benign lymph nodes in the head and neck: how reliable are the results?
    Baghi M, Mack MG, Wagenblast J, Hambek M, Rieger J, Bisdas S, Gstöttner W, Engels K, Vogl T, Knecht R.
    Anticancer Res. 2007 Sep-Oct;27(5B):3571-5.
  19. Dynamic contrast-enhanced CT of head and neck tumors: perfusion measurements using a distributed-parameter tracer kinetic model. Initial results and comparison with deconvolution-based analysis.
    Bisdas S, Konstantinou GN, Lee PS, Thng CH, Wagenblast J, Baghi M, Koh TS.
    Phys Med Biol. 2007 Oct 21;52(20):6181-96. Epub 2007 Oct 1.
  20. Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer.
    Baghi M, Bisdas S, Engels K, Yousefi M, Wagenblast J, Hambek M, Knecht R.
    Clin Otolaryngol. 2007 Oct;32(5):372-7.
  21. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H, Knecht R.
    J Cancer Res Clin Oncol. 2008 Mar;134(3):323-30. Epub 2007 Aug 14.
  22. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.
    Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R.
    Eur J Cancer. 2007 Jul;43(10):1502-7. Epub 2007 May 23.
  23. Primary B cell lymphoma of the sphenoid sinus: CT and MRI characteristics with correlation to perfusion and spectroscopic imaging features.
    Bisdas S, Fetscher S, Feller AC, Baghi M, Knecht R, Gstöttner W, Vogl TJ, Balzer JO.
    Eur Arch Otorhinolaryngol. 2007 Oct;264(10):1207-13. Epub 2007 May 4.
  24. Demands on caring relatives of head and neck cancer patients.
    Baghi M, Wagenblast J, Hambek M, Radeloff A, Gstöttner W, Scherzed A, Spaenkuch B, Yuan J, Hornung S, Strebhardt K, Knecht R.
    Laryngoscope. 2007 Apr;117(4):712-6.
  25. Differentiation of benign and malignant parotid tumors using deconvolution-based perfusion CT imaging: feasibility of the method and initial results.
    Bisdas S, Baghi M, Wagenblast J, Knecht R, Thng CH, Koh TS, Vogl TJ.
    Eur J Radiol. 2007 Nov;64(2):258-65. Epub 2007 Mar 30.
  26. Demands of the caring relatives in head and neck cancer patients.
    Baghi M.
    Laryngoscope. 2007 Feb 23. [Epub ahead of print] No abstract available.
  27. Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies.
    Bisdas S, Baghi M, Smolarz A, Pihno NC, Lehnert T, Knecht R, Mack MG, Vogl TJ, Tuerkay S, Koh TS.
    Invest Radiol. 2007 Mar;42(3):172-9.
  28. Inverse correlation between serum PGE2 and T classification in head and neck cancer.
    Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R.
    Head Neck. 2007 Mar;29(3):244-8.
  29. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
    Baghi M, Mack MG, Hambek M, Bisdas S, Muerthel R, Wagenblast J, Gstöttner W, Vogl T, Knecht R.
    Head Neck. 2007 Feb;29(2):104-8.
  30. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M, Hambek M, Wagenblast J, May A, Gstöttner W, Knecht R.
    Anticancer Res. 2006 Jan-Feb;26(1B):585-90.
  31. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
    Baghi M, Hambek M, May A, Radeloff A, Gstöttner W, Knecht R.
    Anticancer Res. 2006 Jan-Feb;26(1B):559-63.
  32. In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck.
    Bisdas S, Baghi M, Huebner F, Mueller C, Knecht R, Vorbuchner M, Ruff J, Gstöttner W, Vogl TJ.
    Eur Radiol. 2007 Jan;17(1):251-7. Epub 2006 May 16.
  33. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.
    Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R.
    Anticancer Res. 2006 Mar-Apr;26(2A):1091-5.
  34. AdOnco: a database for clinical and scientific documentation of head and neck oncology.
    Hambek M, Adunka O, Baghi M, Gstöttner W, Knecht R.
    Ann Otol Rhinol Laryngol. 2006 Feb;115(2):144-9.
  35. Reduction of cisplatin dosage by ZD 1839.
    Hambek M, Baghi M, Strebhardt K, Baumann H, Gstöttner W, Knecht R.
    Anticancer Res. 2005 Nov-Dec;25(6B):3985-8. Erratum in: Anticancer Res. 2006 May-Jun;26(3a):2187.
    Strebhard, Klaus [corrected to Strebhardt, Klaus].
  36. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
    Hambek M, Baghi M, Baumaun H, Strebhardt K, Adunka O, Gstöttner W, Knecht R.
    Anticancer Res. 2005 May-Jun;25(3B):1871-5. Erratum in: Anticancer Res. 2006 May-Jun;26(3a):2187.
    Strebhard, Klaus [corrected to Strebhardt, Klaus].
  37. The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers.
    Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstöttner W, Knecht R.
    Anticancer Res. 2005 Sep-Oct;25(5):3665-70.
  38. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.
    Hambek M, Baghi M, Strebhardt K, May A, Adunka O, Gstöttner W, Knecht R.
    Anticancer Res. 2004 Nov-Dec;24(6):3881-6. Erratum in: Anticancer Res. 2005 Jan-Feb;25(1b):681.
    Strebhard, Klaus [corrected to Strebhardt, Klaus].
  39. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
    Knecht R, Peters S, Hambek M, Solbach C, Baghi M, Gstöttner W, Hambek M.
    Adv Otorhinolaryngol. 2005;62:81-91.
  40. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
    Knecht R, Peters S, Solbach C, Baghi M, Gstöttner W, Hambek M.
    Anticancer Res. 2003 Nov-Dec;23(6C):4789-95.
Priv. Doz. Dr. med. Mehran Baghi
Priv. Doz. Dr. med. Mehran Baghi
Practice hours
Mon, Tue, Thu: 09.00 - 12.00
Mon, Tue, Thu: 15.00 - 18.00
Wed: 09.00 - 12.00
Fri: 09.00 - 13.00
Leipziger Straße 1, 63179 Obertshausen
Phone: +49 6104 - 71800
Fax: +49 6104 - 75535
e-mail: info@hno-drbaghi.com